American Society of Hematology

Figure 2.

$Figure 2. Inhibition of NF-κB may promote ABC DLBCL cell death. Shown is the outcome of a clinical trial of DA-EPOCH with bortezomib in 27 patients with relapsed/refractory ABC and GCB DLBCL. Overall survival of patients with ABC or GCB DLBCL showed a median survival of 10.8 and 3.4 months, respectively (P = .0026). Patients with ABC DLBCL also had a significantly higher complete and overall response rate compared with patients with GCB DLBCL.$

Inhibition of NF-κB may promote ABC DLBCL cell death. Shown is the outcome of a clinical trial of DA-EPOCH with bortezomib in 27 patients with relapsed/refractory ABC and GCB DLBCL. Overall survival of patients with ABC or GCB DLBCL showed a median survival of 10.8 and 3.4 months, respectively (P = .0026). Patients with ABC DLBCL also had a significantly higher complete and overall response rate compared with patients with GCB DLBCL.

This Feature Is Available To Subscribers Only